Advanced Medical Solutions Grp PLC Holding(s) in Company (2522Y)
May 13 2016 - 10:21AM
UK Regulatory
TIDMAMS
RNS Number : 2522Y
Advanced Medical Solutions Grp PLC
13 May 2016
For filings with the FCA
include the annex
For filings with issuer exclude
the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------------------------------------------
1. Identity of the issuer or Advanced Medical Solutions
the underlying issuer Group plc
of existing shares to which
voting rights are
attached: (ii)
------------------------------------------------------ ------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
--------------------------------------------------------------------------------------
An acquisition or disposal of voting rights ü
------------------------------------------------------- -----------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------- -----------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------- -----------------------------
An event changing the breakdown of voting rights
------------------------------------------------------- -----------------------------
Other (please
specify):
----------------------------------------------------- -----------------------------
3. Full name of person(s) Octopus Investments Nominees
subject to the Limited
notification obligation:
(iii)
------------------------------------------------------ ------------------------------
4. Full name of shareholder(s) n/a
(if different from 3.):(iv)
------------------------------------------------------ ------------------------------
5. Date of the transaction 12/05/2016
and date on
which the threshold is
crossed or
reached: (v)
------------------------------------------------------ ------------------------------
6. Date on which issuer 13/05/2016
notified:
------------------------------------------------------ ------------------------------
7. Threshold(s) that is/are
crossed or
reached: (vi, vii) 8%
------------------------------------------------------ ------------------------------
8. Notified details: n/a
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- --------------------------------- --------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
------------- --------------- ---------------- -------------- ------------------------- -------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------- ----------- ------------ -------------- ----------- ------------ ------------ -----------
GB0004536594 16711714 16711714 16849149 16849149 8.06%
--------------- ---------------- -------------- ----------- ------------ ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
----------------- ------------- -------------------------------- --------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
--------------- ------------- -------------- ---------------- --------------------------- -----------------------
Nominal Delta
--------------- ------------- -------------- ---------------- --------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
-------------------------------------------------- ------------------------------------------------------------------
16849149 8.06%
-------------------------------------------------- ------------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
-----------------------------------------------------------------------
n/a
Proxy Voting:
-----------------------------------------------------------------------
10. Name of the proxy holder: n/a
------------------------------------------------------- --------------
11. Number of voting rights proxy n/a
holder will cease
to hold:
------------------------------------------------------- --------------
12. Date on which proxy holder will n/a
cease to hold
voting rights:
------------------------------------------------------- --------------
13. Additional information:
------------------------------------------------------- --------------
14. Contact name: Niki Read
------------------------------------------------------- --------------
15. Contact telephone number: 020 7776 7969
------------------------------------------------------- --------------
Note: Annex should only be submitted to the FCA not
the issuer
Annex: Notification of major interests in share
A: Identity of the persons or legal entity subject to
the notification obligation
----------------------------------------------------------------
Full name Peter Orsi
(including legal form of
legal entities)
------------------------------------- -------------------------
Contact address 33 Holborn, London, EC1N
(registered office for legal 2HT
entities)
------------------------------------- -------------------------
Phone number & email 020 7710 2877
------------------------------------- -------------------------
Other useful information
(at least legal representative
for legal persons)
------------------------------------- -------------------------
B: Identity of the notifier, if applicable
----------------------------------------------------------------
Full name
------------------------------------- -------------------------
Contact address
------------------------------------- -------------------------
Phone number & email
------------------------------------- -------------------------
Other useful information
(e.g. functional relationship
with the person or legal
entity subject to the notification
obligation)
------------------------------------- -------------------------
C: Additional information
----------------------------------------------------------------
For notes on how to complete form TR-1 please see the
FCA website.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUOASRNWAVAAR
(END) Dow Jones Newswires
May 13, 2016 10:21 ET (14:21 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Apr 2023 to Apr 2024
